Marcuphen

Phenprocoumon, the active ingredient in Marcuphen, is a vitamin K antagonist presented as an oral tablet for oral use. It is employed to prevent and treat thromboembolic disorders in patients at risk of clot formation. GNH USA supplies Marcuphen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marcuphen, a vitamin K antagonist, is used in several thrombo‑preventive pathways. - Venous thromboembolism: prevents clot formation and recurrence in patients at risk. - Atrial fibrillation: reduces the incidence of stroke and systemic embolism in non‑valvular atrial fibrillation. - Orthopedic surgery: provides prophylaxis against postoperative deep‑vein thrombosis and pulmonary embolism after joint replacement or fracture repair.

Phenprocoumon may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Bleeding or bruising: easy bruising, nosebleeds, gum bleeding. - Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia. - Headache or dizziness. - Skin rash or mild itching.

Serious or Rare Side Effects: - Severe hemorrhage: intracranial, gastrointestinal or retroperitoneal bleeding. - Skin necrosis or severe cutaneous reactions. - Allergic anaphylaxis. - Hepatic enzyme elevation. - Thrombocytopenia or other hematologic abnormalities.

Patients receiving Marcuphen require careful monitoring and risk assessment. - Monitor INR: regular blood tests to keep coagulation within therapeutic range. - Assess bleeding risk: evaluate history of ulcers, surgery or trauma before initiation. - Adjust dose in liver impairment: reduced metabolic clearance may increase anticoagulant effect. - Caution in renal dysfunction: monitor for accumulation and bleeding. - Avoid in uncontrolled hypertension: high blood pressure raises hemorrhage risk. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Phenprocoumon interacts with many medicines that affect coagulation or its metabolism.

Major Interactions (Avoid): - Concurrent anticoagulants (e.g., heparin, warfarin): additive bleeding risk. - Strong CYP2C9 inhibitors (e.g., amiodarone, fluconazole, metronidazole): may cause excessive anticoagulation. - Antiplatelet agents (e.g., aspirin, clopidogrel): heightened hemorrhage potential. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): potentiate anticoagulant effect.

Moderate Interactions (Monitor Closely): - Moderate CYP2C9 inhibitors (e.g., macrolide antibiotics, SSRIs): may require dose adjustment. - Herbal supplements (e.g., ginkgo, garlic, ginger): can affect platelet function. - Vitamin K‑rich foods: may reduce anticoagulant efficacy. - Diuretics and ACE inhibitors: monitor blood pressure and renal function.